Early intervention and prediction of onset of kidney failure or injury is very important in initiation of treatment of patient affected with kidney diseases. US FDA approved new biomarker test which find out presence of insulin-like growth-factor binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases (TIMP-2) in the urine with in 20 minutes.
Insulin-like growth-factor binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases (TIMP-2) are associated with kidney injury and its early detection of their presence will help in predicting likeness of Acute Kidney Injury and help in deciding line of treatment.
NephroCheck is the diagnostic test which is a first of its kind test approved by US FDA. FDA have approved this test under De novo premarket approval which promote novel drugs and medicines, medical devices which are prove life saving and event there is no such existing device or drug previously approved for indicated use by US FDA.
NephroCheck is manufactured by California based Astute Medical.
You May Like :
New kidney function test which can precisely predict early onset of kidney failure
New biomarker identified which is linked to increased risk of kidney failure.